 |
OBR green is our dynamic, eco-friendly digital magazine featuring all of our original content. Register to begin receiving OBR green today.
.jpg)
Archived OBR Journal Articles
March 2013 - Table of Contents
July 2012 - Table of Contents
- Ensuring a Compelling Value Proposition in Oncology
- ASCO President Michael P. Link, MD, Addresses the 2012 Annual Meeting
- The Promising Outlook With Immunoconjugate Therapy
- Most Popular News Stories in OBR vs Most Popular in the Media
- PD-1 Immunotherapy Makes a Splash at ASCO
- Spotlight on Cost of Cancer Care: Trastuzumab
- Most Cancer Patients Will Be Treated in Integrated Delivery Networks (IDN) and Cancer Institutions by 2016, Predicts New Report
- On-Conversation with Michael Tardugno, President, CEO, Celsion Corporation
May 2012 - Table of Contents
- The Rise of Companion Diagnostics: A Step Towards Truly Personalized Medicine
- Kantar Health’s Top Picks: What’s Hot at ASCO 2012
- Peter B. Bach, MD, and the Case for Interchangeability in Oncology: A New Model for an Episode-based Payment System
- Achieving Accountable Cancer Care
- On-Conversation with Michael N. Neuss, MD, Chief Medical Officer of the Vanderbilt-Ingram Cancer Center
- Diagnostic Testing and Clinical Pathways Move into the PA Neighborhood
- Spotlight on Cost of Cancer Care: Panitumumab
March 2012 - Table of Contents
- Solid Tumor Agents Dominate the Future of Biomarkers
- After an Eventful 2011, What’s in the Pipeline for Emerging Technologies in Oncology?
- Spotlight on Cost of Cancer Care: Rituximab
- The Use of Hsp90 Inhibitors in the Treatment of Lung Cancer
- Digital Patient Engagement: Next Steps in the Provider-Patient Relationship
January 2012 - Table of Contents
- New Frontiers and Novel Mechanism of Action in Hematologic Malignancies
- Shining a Light: How the Sunshine Provision May Impact Promotion
- Consumerism in Oncology: How Will it Affect Cancer Care?
- The OBR Top 10 Oncology Stories of 2011
- The 4th Annual Outlook on the Pharmaceutical Promotional Landscape Within Oncology
November 2011 - Table of Contents
- On-Conversation with Jeff Patton, MD, Chief Executive Officer Tennessee Oncology, Chief Medical Officer RainTree Oncology Services
- Regional Variances in European Pancreatic Cancer Treatment and the Influential Power of Clinical Trial Participation
- Consolidations Come with Concerns as NCI Cooperative Groups Restructure
- Baker's Dozen Attempting to Beat the Odds in Pancreatic Cancer
- Relating Value in Cancer Care to Cost and Outcome
- Oncologists' Perspectives on the Future of Biosimilars
- Spotlight on Cost of Cancer Care: Bendamustine
September 2011 - Table of Contents
July 2011 - Table of Contents
May 2011 - Table of Contents
March 2011 - Table of Contents
- Payer Trends: Assisting with End of Life Discussions
- Regulating Molecular and Genetic Tests: NCCN Annual Meeting Coverage
- Epigenetics: Moving Beyond the Early Promise
- From Limbaugh, to ODAC, to FDA and Compendia, the Avastin Debate Continues (at least until June)
- Healthcare Reform: A Bitter Pill for Oncology?
January 2011 - Table of Contents
- 2011 Forecast: Experts Provide Perspective on the Coming Year in Oncology
- '10 in Review
- 2013: Five Predictions for the Future of Oncology
- Oncology Market Adoption Trends: Quick Poll Results From ASH & SABCS
- The Oncology Professional Services Agreement
- Seeking an Oncology-Specific Accountable Care Model
- The 3rd Annual Outlook on the Pharmaceutical Promotional Landscape Within Oncology
- Spotlight on Cost of Cancer Care
November 2010 - Table of Contents
- Conference Coverage: Highlights from the 2010 Cancer Center Business Summit
- U.K. & U.S. Cost and Comparative Effectiveness Policies Converge
- Past Pitfalls and Potential Promise for Pancreatic Cancer
- Healthcare Reform: Oncology PAP Program Design in the Age of the Federally Insured
- Spotlight on Cost of Cancer Care
- On-Currences
September 2010 - Table of Contents
- The Rise (and Fall?) of Avastin for the Treatment of Advanced Metastatic Breast Cancer
- Implementation of Clinical Pathways: Payers to Share Savings With Pathway Compliant Groups
- The FDA and Laboratory Developed Tests: The Brouhaha Continues
- Cancer Stem-like Cells: The Evolution of a Cancer Theory
- Prior Authorization—Preventing Waste or Waste of Time?
- On-Currences
July 2010 - Table of Contents
- On-Currences
- The EMR Landscape: A Review of the ASCO 2010 EHR Lab
- Taking It Personal–When to Add Biomarkers to Treatment Guidelines
- Factors Driving the Current and Future Use of Oncology Biomarkers
- Innovative Advancements in Treating Cancer: Beyond Targeted Therapies
- ASCO 2010 Top News Stories
- Payer Reactions to Highly Anticipated Clinical Trial Presentations
May 2010 - Table of Contents
- NCCN: Clinical and Economic Issues Impacting Cancer Care Delivery
- Payers Must Create Defensible Oncology Management Strategies
- Expansion of Section 340B Raises New Questions for Cancer Stakeholders
- Models and Mechanisms for Assisting the Underinsured
- Forecasting Success: the Misperceived Influence of FDA Approval
- Onconversation with James Sabry, MD, PhD, Vice President, Genentech Partnering
- On-Currences
- OBR Radar: Keeping an Eye on Market Moving Events
March 2010 - Table of Contents
- The Ongoing Hopes and Challenges of Cancer Vaccines (Part 2 of 2)
- Managing the Health of Your Patients and Your Practice
- Risk-Sharing Schemes in Oncology—Future or Fad?
- A Perspective on Cancer Drug Pricing and Volume
- OBR Radar: Keeping an Eye on Projected Market Moving Events in the Oncology Pipeline
- ON-CURRENCES
January 2010 - Table of Contents
November 2009 - Table of Contents
- Commercialization of Oncology Medicines and Federal Policy: Why Technology Transfer Offices Should Increase Their Activities on Coverage and Reimbursement Issues
- An Insider’s Guide to Using Oncology-Specific EMRs
- Oncology-Specific EMRs Gain Traction: Suppliers Weigh In
- On-Conversation with Kenneth H. Buetow, PhD
- Attaining Breast Center Accreditation: Merging Market Share Goals with Quality Measures
- Panel Advises on Clinical Pathways: What, Why, and How
- OP-ED: Clinical and Operational Benchmarking With EMRs
- ON-CURRENCES
- IB/MAB WORKSHEET
September 2009 - Table of Contents
- Defining Meaningful Use Criteria for Electronic Health Records: An Early Adopter’s Wish List
- The Increasing Incidence of Special Protocol Assessments
- Compliance Programs Partner in the Management of Oral Cancer Therapies
- Battling the High Cost of Nonadherence with Oral Cancer Therapies
- Oncologists: Cost-Effectiveness Policy Necessary Despite Quality of Care Warnings
- ONCOLOGY BOOK REVIEWS
- ON-CURRENCES
July 2009 - Table of Contents
- The Debate Over Episode-Based Payments in Oncology—Can This System Replace Buy and Bill?
- ACCME Regulation Takes Affect—Changing the CME Industry For Better or For Worse
- Select Biomarkers Possibly Ready for Primetime: EGFR, HER2, and K-ras
- Economy Forcing Oncology Groups to Adjust Business Practices
- ERA-Based Data and Oncology Products: An Opportunity for Practices to Maximize Cash Flow
- ON-CURRENCES
May 2009 - Table of Contents
- Detecting the Future: A Perspective on the Rising Value of Diagnostics in Oncology Therapeutics (Part 2)
- A Bump in the Road: Laboratory Developed Tests Defend Their Regulatory Position
- Competing for Image Leadership
- Adoption of e-Prescribing Yields Surprising Benefits to Practices
- Clinical Trial Landscape in Breast Cancer – Survey From March '09
- ONCOLOGY BOOK REVIEWS
- ON-CURRENCES
March 2009 - Table of Contents
- OP-ED: Innovative Cancer R&D – Here to Stay
- Tension Rises as Three Products for Hard-to-Treat Tumors Reach a Pivotal Point
- Detecting the Future: A Perspective on the Rising Value of Diagnostics in Oncology Therapeutics (Part 1)
- A P&T Perspective on Adoption of Clinical Guidelines by Payers
- Promising Pipeline Pearls on the Horizon
- Changes in Oncology Practice Business Models Require Changes in Oncology Marketing Strategies: A Case Study Elucidates the Business Model Changes
- Pipeline Perspectives™: Biomerk Tumorgrafts™—An Alternative Approach to Xenografts
- ON-CURRENCES
January 2009 - Table of Contents
- CCBS COVERAGE: Community Oncology at the Crossroads
- The New Administration’s Health Policy and What it Means to You
- ’09 Forecast: Oncology Stakeholders Provide Perspective on the Coming Year
- ’08 Review: Top 10 Oncology Stories & The Roller Coaster Year for Select Companies
- Targeted Agents Primed to Benefit in Wake of Recent Genomic Data
- Still Using Pen & Paper?
- An Outlook on the Pharmaceutical Promotion Landscape Within Oncology
- ON-CURRENCES
November 2008 - Table of Contents
- Oncology Compendia: Greater Transparency and Regulatory Attention at the Forefront
- Prospecting In Oncology: Analytical Framework Guides Development Strategy Decisions
- Creating Comparative Effectiveness Policy: How Does Oncology Fit?
- Productive Partnering—The Next Stage in Patient Enrollment for Clinical Trials
- Oncology Clinical Trials: The New Battleground?
- Planning to Maximize the Economics of Clinical Trials
- ON-CONVERSATIONS: HillCo Partners Identifies Major Healthcare Policy Trends Which Will Impact Oncology Over the Next 3 to 5 Years
- ON-CURRENCES
September 2008 - Table of Contents
- DDMAC and the Debate Over Off-Label Communications
- The Oncology Pipeline: Maturing, Competitive, and Growing?
- Targeting Therapy: New Approaches to Finding the Next Great Cancer Drug
- Companion Biomarkers and Cancer Treatment: Lessons Learned for Oncology New Product Planning
- Tearing Down Walls: Payers and Providers Align Quality Care and Reimbursement
- Onmark 3rd Annual Office-based Oncology Business Benchmarking Survey: 2008 Report on 2007 Data
July 2008 - Table of Contents
- Perceptions in Oncology Drug Strengths and Weaknesses: Zitter Group Survey Shows Similarities and Disparities Between Payers and Providers
- As the Importance of Biomarkers Increases, Academia and Industry Consider How Best to Respond
- The Physician’s Role in Securing Patient Access to Appropriate Therapies: Sharing the Stage with Patients and Payers
- ASCO '08: Media, Giveaways, and Foot Traffic
- ASCO '08: A Look at the Progress in 3 Different Cancer Types
- ASCO '08: The Competition for Share of Voice Descends Upon Chicago,
- ON-CONOMY: Medicare Policies Change ESA Use and Payment
May 2008 - Table of Contents
- Pioneers in Personalized Medicine—Agendia and Genomic Health Are Changing the Way Patients with Breast Cancer Are Treated
- Cutting Through the Noise: Gaining and Maintaining Share of Voice in Today’s Oncology Marketplace
- Patient Assistance Programs: Good Business & Good Will Go Hand in Hand
- Oncology Drug Denials Slow Payment in Q4 ‘07
- Emerging mTOR Inhibitors Make Good on Their Initial Promise
- Back to the Future: Original Liquid Leukine® Coming Soon
March 2008 - Table of Contents
- Behind Closed Network Doors: Oral Cancer Drugs and the Rise of Specialty Pharmacy
- Weathering the Storm: How Genentech Looks to Rebuild Confidence and Ride on to Continued Success in 2008
- Celebrating 25 Years of the Orphan Drug Act
- ESA Policy Raises Hospital Admissions for Transfusions
- Restricted Access: What Happens If the Door Closes to Industry?
- On–Conversation with Daniel Swisher, CEO and President, Sunesis Pharmaceuticals Inc.
January 2008 - Table of Contents
- Compendia: The Bridge Between FDA Approved Indications and Off-label Drug Usage
- The Appeal of Genasense: The Drug, the Data, and the Tangled Web that its FDA Review has Become
- How Does Drug Pricing Drive Therapeutic Choice? A review of a symposium held in conjunction with the American Society of Hematology (ASH)
- ’07: In Review. The OBR Top 10 Media Stories & Top 10 Deals of 2007
- ’08: Forecast (Part 1). Oncology Industry Experts Provide Perspective on the Coming Year
- ’08: Forecast (Part 2) The View From the Office: How Community Oncologists See 2008
- Tasigna®: An Innovative TKI from Novartis for Patients with CML
- Biogen Idec: An Oasis for Employees During the Southern California Wildfires
November 2007 - Table of Contents
- Zero Sum Game
- Rituxan® Anniversary: 10 Years of Progress
- The Future of the Present: A Look at the Current and Proposed State Legislature to Regulate and Disclose Gifts
- Evolution of the Oncology GPO
- A New Kind of Cancer Warfare Agent: Next Generation Monoclonal Antibodies
- On-Conversation with Paolo Paoletti, MD, Senior Vice President, Oncology Medicine Development Center, GlaxoSmithKline
- On-Conversation with Craig W. Philips, Vice President & General Manager, Bayer Healthcare
September 2007 - Table of Contents
- Radiopharmaceuticals Need a Jump-STaRT
- The Alphabet Soup of Hematologic Malignancies: Current Therapies Point the Way to Future Breakthroughs
- Ink and Inc.: How ASCO’s Media Policies Affect the Oncology Industry
- Making a Splash at ASCO
- Torisel™: The New Kid on the Block for Advanced Renal Cell Carcinoma
- On-Conversation with Nancy Simonian, M.D.
- On-Conversation with Craig Eagle, Senior Director, Global Oncology, Pfizer Global Pharmaceuticals
- On-Conversation with Bob Oliver, VP & Global Business Manager of the Oncology Franchise at Wyeth Pharmaceuticals
June 2007 - Table of Contents
- The Rising Tide of Generic Cancer Agents
- To Dispense Or Not To Dispense
- Understanding Operational and Financial Benchmarks In The Practice
- GPC Biotech and the Satraplatin Story
- Q&A With David Parkinson, MD, Senior VP of R&D at BiogenIdec
- Oncology Sales Force Effectiveness In An Era of Unprecedented Competition (A Look Ahead)
May 2007 - Table of Contents
- Tykerb: In a Class By Itself
- Therapeutic Cancer Vaccines: The Road to Commercialization
- A Tale of Two Cancer Immunotherapy Companies: Same Tumor Target, Parallel Development, and Very Different Approaches
- Challenges in Reimbursement: Communicating Non-reimbursed Costs to Payers
- Of Mice and MAbs: Medarex
- Improving Compliance in the World of Biotechs: Helping Small Companies Avoid Big Problems
February 2007 - Table of Contents
- Dendreon Steps Up to the Plate, And Cancer Immunotherapy Companies Watch from the Sidelines
- Therapeutic Cancer Vaccines: Elucidating the Differences Between Passive and Active Immunotherapy
- The Science behind Developing Active Immunotherapies: A Look at NHL and Prostate Cancer Therapeutic Vaccines
- Office Practice Managers Speak Their Minds
- OBR Q&A with Michael King, Director of Research at Rodman & Renshaw
- Medicare’s Competitive Acquisition Program: Stats Reveal Who’s In/Who’s Out and Why
January 2007 - Table of Contents
- Spotlight on Exelixis: Big Pipeline—Big Deals—Big Promise?
- Clinical Pathways: Can the Art of Oncology be Managed?
- The Vectibix™ Launch: A Look at the Commercialization of this New Fully-Humanized Antibody for Colorectal Cancer
- Competitive Landscape: Designing the Next Cancer Drugs
- Strategies for Gaining Cancer Drug Approval in '07
- Molecular Profiling: Using the Genome to Identify Effective Cancer Agents
- Ariad Aligns with Bellicum to Develop Novel Vaccine for Prostate Cancer
September 2006 - Table of Contents
- Spotlight On Celgene: A Cancer Company On The Rise
- Exhibitor Bang For The Buck? A Look at ASCO Exhinit Hall Floor
- Oral Cancer Agents Are Changing The Distribution Channel
- Big Pharma Has A Big ASCO ‘06
- Interpretation Of Survival Data From Oncology Clinical Trials
- mTOR INHIBITORS: Will They Redefine The Blockbuster In Cancer Therapy